Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Meeker – Chairman, Chief Executive Officer and President Jennifer Lee – Executive Vice President, Head-North America Hunter Smith – Chief Financial Officer Yann Mazabraud – Executive Vice President, Head-International Conference Call Participants Derek Archila – Wells Fargo Seamus Fernandez – Guggenheim Securities Phil Nadeau – TD Cowen Whitney Ijem – Canaccord Genuity Tazeen Ahmad – Bank of America Joseph Stringer – Needham & Company Leland Gershell – Oppenheimer Anthea Li – Jefferies Ram Selvaraju – H.C. Wainwright & Company Jon Wolleben – Citizens JMP Operator Good day, and welcome to Rhythm Pharmaceuticals Fourth Quarter and Fiscal Year 2024 Earnings Conference Call.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet
The consensus price target hints at a 26.4% upside potential for Rhythm Pharmaceuticals (RYTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldman Sachs Group, Inc. Seamus Fernandez - Guggenheim Securities Dae Gon Ha - Stifel, Nicolaus & Company, Inc. Whitney Ijem - Canaccord Genuity Corp. Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Joseph Stringer - Needham & Company Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
